Abstract
For many years studies on the atherosclerotic plaque as well as animal, genetic, metabolic and epidemiologic studies have suggested a causal relationship between hypercholesterolemia and coronary artery disease. However, the best evidence which influences our thinking regarding this relationship comes from controlled research trials in man.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
A co-operative trial in the primary prevention of ischaemic heart disease using Clofibrate: report from the Committee of Principal Investigators. Br Heart J 1978;40:1069–1118.
Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351–364.
Frick MH, Elo 0, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237–1245.
The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360–381.
Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245–1255.
Brensike JF, Levy RI, Kelsey SF, et al: Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: Results of the NHLBI Type II Coronary Intervention Study. Circulation 1984;69:313.
Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233–3240.
Consensus Development Conference. Lowering blood cholesterol to prevent heart disease. JAMA 1985;253:2080–2086.
The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36–69.
National Institutes of Health Consensus Congerence on the Treatment of Hypertriglyceridemia. JAMA 1984;251:9.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Kluwer Academic Publishers
About this chapter
Cite this chapter
Morganroth, J. (1989). What are the Recommendations to the Medical Community to Institute Hypolipidemic Therapy?. In: Morganroth, J., Moore, E.N. (eds) Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents. Developments in Cardiovascular Medicine, vol 100. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1605-3_12
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1605-3_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8888-6
Online ISBN: 978-1-4613-1605-3
eBook Packages: Springer Book Archive